Roth Capital Initiates Coverage on Glaukos Corp(NYSE:GKOS). The shares have been rated Buy. The rating by Roth Capital was issued on Apr 14, 2016.
In a different note, On Mar 2, 2016, JP Morgan said it Maintains its rating on Glaukos Corp. In the research note, the firm Lowers the price-target to $32.00 per share. The shares have been rated ‘Overweight’ by the firm. Piper Jaffray said it Initiates Coverage on Glaukos Corp, according to a research note issued on Feb 9, 2016. The shares have been rated ‘Overweight’ by the firm.
Glaukos Corp (GKOS) made into the market gainers list on Mondays trading session with the shares advancing 3.02% or 0.56 points. Due to strong positive momentum, the stock ended at $19.11, which is also near the day’s high of $19.26. The stock began the session at $18.56 and the volume stood at 1,48,883 shares. The 52-week high of the shares is $33.92 and the 52 week low is $14.25. The company has a current market capitalization of $618 M and it has 3,23,40,033 shares in outstanding.
Glaukos Corp(GKOS) last announced its earnings results on Mar 1, 2016 for Fiscal Year 2015 and Q4.Earnings per share were $-0.07.
Several Insider Transactions has been reported to the SEC. On Jan 4, 2016, Richard L Harrison (CFO) purchased 1,388 shares at $15.30 per share price.Also, On Jan 4, 2016, Thomas William Burns (CEO) purchased 1,388 shares at $15.30 per share price.On Jun 30, 2015, Robert J More (director) purchased 5,000 shares at $18.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.